Type of security: Stock
Sector: Health Care
Industry: Medical/Nursing Services
The data is delayed by 15 minutes.
Description: Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotech and specialty pharmaceuticals. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company offers its solutions in range of specialty therapeutic categories, including oncology, immunology, hepatitis, multiple sclerosis, HIV, and infusion therapy. Diplomat Pharmacy, Inc. has seven pharmacy locations in Michigan, Illinois, Florida, California, Connecticut, and Massachusetts. The company was founded in 1975 and is headquartered in Flint, Michigan.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||15.36%||Sales Growth - Q/Q||2.09%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||1.09%||ROE||1.86%||ROI|
|Current Ratio||2.09||Quick Ratio||1.58||Long Term Debt/Equity||Debt Ratio||0.66|
|Gross Margin||6.39%||Operating Margin||0.48%||Net Profit Margin||0.25%||Dividend Payout Ratio|
|Cash From Financing Activities||152.07 M||Cash From Investing Activities||-3.91 M||Cash From Operating Activities||-4.1 M||Gross Profit||41.14 M|
|Net Profit||2.86 M||Operating Profit||4.84 M||Total Assets||544.8 M||Total Current Assets||444.79 M|
|Total Current Liabilities||212.69 M||Total Debt||4.7 M||Total Liabilities||224.46 M||Total Revenue||624.88 M|
|High 52 week||21.15||Low 52 week||4.31||Last close||4.69||Last change||2.18%|
|RSI||24||Average true range||0.25||Beta||1.12||Volume||808.56 K|
|Simple moving average 20 days||-6%||Simple moving average 50 days||-13.56%||Simple moving average 200 days||-33.15%|
|Performance Week||-1.26%||Performance Month||-16.55%||Performance Quart||-12.66%||Performance Half||-14.57%|
|Performance Year||-77.39%||Performance Year-to-date||-69.14%||Volatility daily||2.13%||Volatility weekly||4.77%|
|Volatility monthly||9.77%||Volatility yearly||33.85%||Relative Volume||189.12%||Average Volume||742.77 K|
|New High||New Low|
2019-11-15 06:40:28 | Diplomat Pharmacy, Inc. Just Reported And Analysts Have Been Cutting Their Estimates
2019-11-14 01:55:56 | Edited Transcript of DPLO earnings conference call or presentation 12-Nov-19 1:30pm GMT
2019-11-12 15:36:00 | Diplomat Pharmacy’s stock plunges toward record low after ‘going concern’ warning
2019-11-12 14:11:13 | Diplomat Pharmacy Has 'Substantial Doubt' It Can Continue Operations
2019-11-12 08:55:01 | Diplomat Pharmaceuticals DPLO Reports Q3 Loss, Tops Revenue Estimates
2019-11-12 07:30:00 | Diplomat Announces 3rd Quarter Financial Results; Updates 2019 Guidance
2019-11-06 14:14:51 | Hedge Funds Have Never Been Less Bullish On Diplomat Pharmacy Inc DPLO
2019-10-30 16:30:00 | Diplomat to Release Third-Quarter 2019 Operating Results Nov. 12
2019-10-02 16:30:00 | Diplomat Announces Promotion of David Skomo to Chief Operating Officer of CastiaRx
2019-09-02 12:37:31 | Does Diplomat Pharmacy NYSE:DPLO Have A Healthy Balance Sheet?
2019-08-14 14:36:00 | Diplomat Pharmacy Considers Its Options
2019-08-10 15:45:36 | Edited Transcript of DPLO earnings conference call or presentation 9-Aug-19 12:30pm GMT
2019-08-09 19:23:23 | Diplomat Pharmacy Inc DPLO Q2 2019 Earnings Call Transcript
2019-08-09 07:53:37 | Diplomat Pharmacy Reports Q2 Earnings Beat, Will Explore Strategic Alternatives
2019-08-09 07:31:00 | Diplomat Announces 2nd Quarter Financial Results; Updates 2019 Guidance
2019-08-09 07:30:00 | Diplomat Announces Review of Strategic Alternatives
2019-08-08 17:30:00 | Diplomat signs exclusive practice-based infusion agreement with Allergy Partners
2019-08-08 14:13:09 | Diplomat Pharmacy's Q2 Earnings Preview
2019-08-01 09:27:43 | Is Diplomat Pharmacy, Inc. NYSE:DPLO Trading At A 41% Discount?
2019-07-18 16:30:00 | Diplomat to Release Second-Quarter 2019 Operating Results August 9
2019-07-09 16:30:00 | Diplomat Launches Empower Ecosystem Patient Support Digital Library
2019-06-27 13:21:15 | Rite Aid RAD Incurs Loss in Q1, Revenues Decline Y/Y
2019-06-26 18:29:41 | Here’s What Hedge Funds Think About Diplomat Pharmacy Inc DPLO
2019-06-26 13:26:43 | Is It Too Late To Consider Buying Diplomat Pharmacy, Inc. NYSE:DPLO?
2019-06-26 13:23:22 | Is There Now An Opportunity In Diplomat Pharmacy, Inc. NYSE:DPLO?
2019-05-13 16:54:00 | Waiting on Diplomat Pharmacy to Rebuild
2019-05-10 10:31:02 | New Strong Sell Stocks for May 10th
2019-05-07 15:27:23 | Edited Transcript of DPLO earnings conference call or presentation 7-May-19 12:30pm GMT
2019-05-07 13:23:28 | Diplomat Pharmacy Inc DPLO Q1 2019 Earnings Call Transcript
2019-05-07 09:05:01 | Diplomat Pharmaceuticals DPLO Reports Q1 Loss, Tops Revenue Estimates
2019-05-07 07:59:18 | Diplomat Pharmaceuticals: 1Q Earnings Snapshot
2019-05-07 07:30:00 | Diplomat Announces 1st Quarter Financial Results
2019-05-06 16:30:00 | Diplomat Appoints Dave Loschinskey as Chief Operating Officer
2019-05-03 10:15:14 | Is Diplomat Pharmacy Inc DPLO A Good Stock To Buy?
2019-04-30 10:32:02 | Diplomat Pharmaceuticals DPLO Expected to Beat Earnings Estimates: Should You Buy?
2019-04-25 21:27:18 | APRIL 25 DEADLINE: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Diplomat Pharmacy, Inc. DPLO and Encourages DPLO Investors to Contact the Firm
2019-04-25 16:30:00 | Diplomat Using SMRxT Technology to Enhance Patient Care